Vascular endothelial growth factor-2: Phase IIb ongoing

FDA partially lifted a hold on the Phase IIb GENASIS trial, which allows the company to analyze the data collected so far. VEGF said it will lock the trial database on Aug. 14 and expects follow-up da...